BRAF and hepatocellular carcinoma: However, another case report for an NSCLC and HCC patient receiving sorafenib has demonstrated the efficacy of sorafenib in managing the lung lesions with BRAF G469V mutation, while no response was observed in the hepatic lesions with wild-type (wt) B-RAF.